AMENDMENTS TO THE CLAIMS

- (Previously presented) A transgenic non-human mammal carrying a GANP gene transferred thereinto or its progeny.
- 2. (Previously presented) The transgenic non-human mammal according to claim 1 wherein the transferred GANP gene is expressed in B cells, or its progeny.
- 3. (Previously presented) The transgenic non-human mammal according to claim 1 or 2 wherein the mammal has been generated from GANP gene-transfected ES cells, or its progeny.
- 4. (Currently amended) The transgenic non-human mammal according to any one of claims 1 to
 3 claim 1 wherein the mammal is mouse, or its progeny.
- 5. (Currently amended) A part of the transgenic non-human mammal according to any one of claims 1 to 4 claim 1 or its progeny.
- 6. (Currently amended) A method of producing a high affinity antibody, comprising administering an antigen to the transgenic non-human mammal according to any one of claims 1 to 4 claim 1 or its progeny and recovering the antibody from the resultant mammal or progeny.

Application No.: Not Yet Assigned Docket No.: 4456-0104PUS1

7. (Original) A high affinity antibody obtainable by the method according to claim 6, or a fragment thereof.

- 8. (Original) The antibody according to claim 7 wherein the affinity is 1 x 10⁻⁷ M or less as expressed as a dissociation constant, or a fragment thereof.
- 9. (Original) The antibody according to claim 7 or 8 which is a polyclonal or monoclonal antibody, or a fragment thereof.
- (Original) A humanized antibody or human antibody, or a fragment thereof, comprising the
 V region of the antibody according to claim 9 or a fragment thereof.
- 11. (Currently amended) A pharmaceutical composition comprising at least one selected from the group consisting of the antibody according to any one of claims 7 to 9 claim 7 or a fragment thereof, and the humanized antibody or human antibody, or a fragment thereof.

 according to claim 10.
- 12. (Currently amended) A high affinity-antibody producing cell which is taken from the transgenic non-human mammal according to any one of claims 1 to 4 claim 1 or its progeny, wherein said transgenic mammal or its progeny has been administered an antigen.